Form 8-K Korro Bio, Inc. For: Aug 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oil surges 5%, Brent and US crude both over $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- Rogers adds Sportsnet+ content to Xfinity TV packages for free
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Korro Bio files ethics submission for urea cycle disorder drug trial
August 19, 2026 4:08 PM EDTKorro Bio (NASDAQ: KRRO) announced a submission to the Australian Alfred Health Human Ethics Committee to initiate a first-in-human Phase 1/2 clinical trial for its drug candidate KRRO-121, according to a company statement.
KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide in development for the... More
